Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026
Short Bowel Syndrome With Intestinal Failure: Healthcare Resource Utilization and Cost of Care in a Large US Claims Database.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ali Ahan, Micic Dejan, Gallivan Mark, Kulkarni Aishwarya, Henderson Jeff, Mitchell Gail
Аннотация
OBJECTIVES: This retrospective, real-world analysis aimed to evaluate healthcare resource utilization (HCRU) and associated costs for patients with short bowel syndrome with intestinal failure (SBS-IF), who are dependent on parenteral support (PS), to provide insights into the disease burden.
METHODS: A rules-based algorithm identified and characterized patients with SBS-IF from 2019 to 2023 using Komodo Healthcare Map™ administrative claims data. HCRU and cost data were analyzed across the full cohort and subcohorts of age (3-17, 18-44, ≥45 years), nutrition claims/week (<0.5, 0.5-0.99, ≥1), and time since short bowel syndrome (SBS) surgery (<6 months vs >12 months since PS start).
RESULTS: Among 1587 patients with SBS-IF (mean follow-up 2.75 years), comorbidities included esophageal disorders, anxiety/depression, and liver and kidney disorders. SBS-IF management carried mean annualized costs of $166 483 for the full cohort, and up to $200 000 in the subcohort with ≥1 nutritional claim/week. Inpatient costs were highest, followed by home care costs. Overall mean annualized home care costs were $29 819. Patients with ≥1 nutrition claim/week had the highest nutrition costs ($68 235), driven by parenteral nutrition costs ($55 349). Bloodstream infections (BSIs) occurred in 47% of patients. Patients with BSIs had higher mean annualized costs of $241 868 and a longer median length of stay vs the full cohort (14 vs 8.1 days).
CONCLUSIONS: SBS-IF represents a considerable burden, particularly in younger patients and those with greater nutritional needs, with high healthcare resource use, and substantial associated costs.
METHODS: A rules-based algorithm identified and characterized patients with SBS-IF from 2019 to 2023 using Komodo Healthcare Map™ administrative claims data. HCRU and cost data were analyzed across the full cohort and subcohorts of age (3-17, 18-44, ≥45 years), nutrition claims/week (<0.5, 0.5-0.99, ≥1), and time since short bowel syndrome (SBS) surgery (<6 months vs >12 months since PS start).
RESULTS: Among 1587 patients with SBS-IF (mean follow-up 2.75 years), comorbidities included esophageal disorders, anxiety/depression, and liver and kidney disorders. SBS-IF management carried mean annualized costs of $166 483 for the full cohort, and up to $200 000 in the subcohort with ≥1 nutritional claim/week. Inpatient costs were highest, followed by home care costs. Overall mean annualized home care costs were $29 819. Patients with ≥1 nutrition claim/week had the highest nutrition costs ($68 235), driven by parenteral nutrition costs ($55 349). Bloodstream infections (BSIs) occurred in 47% of patients. Patients with BSIs had higher mean annualized costs of $241 868 and a longer median length of stay vs the full cohort (14 vs 8.1 days).
CONCLUSIONS: SBS-IF represents a considerable burden, particularly in younger patients and those with greater nutritional needs, with high healthcare resource use, and substantial associated costs.